This Data Center Stock Is Up 1,300% in Just 3 Years

Vertiv (VRT) has exceptional price momentum and is hitting new all-time highs. VRT maintains a 100% “Buy” opinion from ...
Nasdaq

NVO Stock Rises on Upbeat Phase III Data for Cagrilintide in Obesity

Novo Nordisk NVO announced positive data from a sub-analysis of its phase III REDEFINE 1 study assessing the efficacy and safety of once-weekly cagrilintide 2.4 mg as a monotherapy, alongside ...
Seeking Alpha

Amylyx anticipates Avexitide Phase III data in H1 2026 while expanding rare disease pipeline

The company expects to complete recruitment for the Phase III LUCIDITY trial of Avexitide by the end of 2025, with top line data anticipated in the first half of 2026. Top line data from the Phase IIb ...